Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: Prognostic significance of autoantibodies - EORTC 18991

Journal of Clinical Oncology

Volumn 28, Issue 14, 2010, Pages 2460-2466

  Bouwhuis, Marna G ^a   Suciu, Stefan ^a   Testori, Alessandro ^a   Kruit, Wim H ^a   Salès, François ^a   Patel, Poulam ^a   Punt, Cornelis J ^a   Santinami, Mario ^a   Spatz, Alain ^a   Ten Hagen, Timo L M ^a   Eggermont, Alexander M M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; PEGINTERFERON ALPHA2B; THYROGLOBULIN ANTIBODY; ALPHA2B INTERFERON; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; OBSERVATION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; ADJUVANT CHEMOTHERAPY; BLOOD; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHADENECTOMY; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SKIN TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTINUCLEAR; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952469658     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.6264     Document Type: Article

References (27)

1. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001 (Pubitemid 32786275)
2. Kirkwood JM, Manola J, Ibrahim J, et al: A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10:1670-1677, 2004 (Pubitemid 38435557)
3. Wheatley K, Ives N, Hancock B, et al: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252, 2003 (Pubitemid 37069655)
4. Wheatley K, Ives N, Eggermont A, et al: Interferon alpha as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol 25:478s, 2007 (suppl; abstr 8526)
5. Gogas H, Ioannovich J, Dafni U, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718, 2006 (Pubitemid 43247141)
6. Satzger I, Meier A, Schenck F, et al: Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 121:2562-2566, 2007 (Pubitemid 350022429)
7. Eggermont AM, Suciu S, MacKie R, et al: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet 366:1189-1196, 2005 (Pubitemid 41393597)
8. Hansson J, Aamdal S, Bastholt L, et al: Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma. Eur J Cancer 6:4, 2007 (suppl 5)
9. Bouwhuis MG, Suciu S, Collette S, et al: Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 101:869-877, 2009
10. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983 (Pubitemid 14202071)
11. Eggermont AM, Suciu S, Santinami M, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 372:117-126, 2008 (Pubitemid 351952257)
12. Glue P, Fang JW, Rouzier-Panis R, et al: Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data - Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 68:556-567, 2000
13. Eggermont AMM, Bouwhuis MG, Kruit WH, et al: Serum concentrations of pegylated interferon alpha-2b in resected stage III melanoma patients receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol 65:671-677, 2010
14. Bukowski RM, Tendler C, Cutler D, et al: Treating cancer with PEG Intron: Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 95:389-396, 2002 (Pubitemid 34787605)
15. Ho V, McLean A, Terry S: Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol 14:166-168, 2008
16. Kee KM, Lee CM, Wang JH, et al: Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. J Gastroenterol Hepatol 21:319-326, 2006
17. Martins EV Jr, Gaburri AK: Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C. Arq Gastroenterol 41:132-133, 2004
18. Soultati AS, Dourakis SP, Alexopoulou A, et al: Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 13:1292-1294, 2007 (Pubitemid 46592980)
19. Tosone G, Borgia G, Gentile I, et al: A case of pegylated interferon alpha-related diabetic ketoacidosis: Can this complication be avoided? Acta Diabetol 44:167-169, 2007
20. Smeenk RJ, Lucassen WA, Swaak TJ: Is anticardiolipin activity a cross-reaction of anti-DNA or a separate entity? Arthritis Rheum 30:607-617, 1987
21. van Dam AP, Wekking EM, Callewaert JA, et al: Psychiatric symptoms before systemic lupus erythematosus is diagnosed. Rheumatol Int 14:57-62, 1994 (Pubitemid 24256823)
22. Kalbfleisch JD, Prentice RL: The Survival Analysis of Failure Time Data (ed 2). Hoboken, NJ, Wiley Inter-Science, 2002
23. Polman CH, Kappos L, Dahlke F, et al: Interferon beta-1b treatment does not induce autoantibodies. Neurology 64:996-1000, 2005 (Pubitemid 40388450)
24. Shovman O, Gilburd B, Barzilai O, et al: Evaluation of the BioPlex 2200 ANA screen: Analysis of 510 healthy subjects - Incidence of natural/predictive autoantibodies. Ann N Y Acad Sci 1050:380-388, 2005 (Pubitemid 41129457)
25. Solans-Laqué R, Perez-Bocanegra C, Salud-Salvia A, et al: Clinical significance of antinuclear antibodies in malignant diseases: Association with rheumatic and connective tissue paraneoplastic syndromes. Lupus 13:159-164, 2004 (Pubitemid 38478641)
26. Tan EM, Feltkamp TE, Smolen JS, et al: Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 40:1601-1611, 1997
27. Imran A, Neelam F, Tariq M: Incidence of circulating antinuclear antibodies in cancer patients. Indian J Med Sci 57:113-116, 2003